Accessibility Menu
Endra Life Sciences logo

Endra Life Sciences(NASDAQ) NDRA

Market Cap$6.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-28%
1 Month-4%
$4.73
-2.67%
-0.13Today
Endra Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 4.782026-07-27
Endra Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.34%USD 4.952026-07-20
1 month-4.21%USD 4.992026-06-26
3 month+4.25%USD 4.592026-04-28
Year to date+5.52%USD 4.532025-12-31
1 year-27.58%USD 6.602025-07-25
3 year-99.78%USD 2,205.002023-07-28
5 year-99.99%USD 64,050.002021-07-28
Since inception-100%USD 136,500.142017-06-30

Endra Life Sciences Financials at a Glance

Market Cap

$6.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.30M

EPS (TTM)

-$8.15

P/E Ratio

-0.60

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$4.73

Volume

99

Open

$4.99

Previous Close

$4.73

Daily Range

$4.73 - $4.99

52-Week Range

$2.96 - $9.85

Estimated Earnings Date

Aug 13, 2026

NDRA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Endra Life Sciences

ENDRA helps doctors measure liver fat without surgery or needles. Its main device connects to standard ultrasound machines. This technology aims to make liver disease checks easier and less costly.

Gadgets That Listen: Products and Services

  • TAEUS Liver Device: Non-invasive tool for measuring liver fat, used with standard ultrasound systems. (0% of revenue in 2025)
  • Thermo-Acoustic Enhanced Ultrasound (TAEUS): Platform for imaging tissue differences, targeting liver and other organs. (0% of revenue in 2025)
  • Temperature Monitoring: Technology for tracking heat during certain surgeries, still in development. (0% of revenue in 2025)
  • Vascular Imaging and Tissue Perfusion: Tools for viewing blood flow and tissue health, under development. (0% of revenue in 2025)
  • Digital Asset Treasury: Investment in digital tokens to manage company funds. (0% of revenue in 2025)

Plot Twists: Growth and Expansion

  • Signed research agreement with General Electric for technology collaboration (year not specified).
  • Launched Digital Asset Treasury initiative with Arca Investment Management in 2025.
  • Reduced workforce and shifted focus to product development in 2026.
  • Began evaluating strategic alternatives, including possible mergers or asset sales, in March 2026.

Why ENDRA Is a Bit Different

ENDRA’s technology works with existing ultrasound machines, aiming to lower costs for clinics. Its patent portfolio covers both U.S. and international markets. The company also invests in digital assets to diversify its capital.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025.
  • Net loss was $7.0 million in 2025, improved 39% from 2024.
  • Cash was $0.76 million at December 31, 2025, down 76% from 2024.
  • Operating expenses fell 47% in 2025 after cost-cutting measures.

Bottom Line

ENDRA is a small medical technology company focused on liver diagnostics. It faces ongoing financial challenges but continues to develop new imaging solutions.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11

CEO

Alexander Y. Tokman

Website

www.endrainc.com

Headquarters

Ann Arbor, MI 48105-1570, US

NDRA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-513.22%

Return on Capital

-209.38%

Return on Assets

-212.39%

Earnings Yield

-1.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.27M

Volume

99

Avg. Volume

31.00K

Financials (TTM)

Gross Profit

-$39.72K

Operating Income

-$6.47M

EBITDA

-$7.15M

Operating Cash Flow

-$5.01M

Capital Expenditure

-$3.00M

Free Cash Flow

-$8.01M

Cash & ST Invst.

$356.46K

Total Debt

$461.21K

Endra Life Sciences Performance Analysis

Endra Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Endra Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Endra Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -7,976.85-17.8%
20232023-12-31USD -2,766.52-65.3%
20242024-12-31USD -56.94-97.9%
20252025-12-31USD -8.93-84.3%
Endra Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.1%
Q32025-09-30-22.8%
Q42025-12-31-55.2%
Q12026-03-3166.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$39.72K

N/A

Gross Margin

0.00%

N/A

Market Cap

$6.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$561.15K

N/A

Employees

11

N/A

Net Income

-$1.31M

-26.5%

EBITDA

-$1.27M

-28.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$356.46K

-82.7%

Total Debt

$461.21K

-21.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$327.25K

-29.0%

Short Term Debt

$133.95K

+6.2%

Return on Assets

-2.12%

N/A

Return on Invested Capital

-2.48%

N/A

Free Cash Flow

-$1.12M

+14.6%

Operating Cash Flow

-$1.12M

+13.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HSCSHeartSciences Inc.
$2.53+5.86%
MOVECorvex, Inc.
$12.64+1.12%
BGMSBio Green Med Solution, Inc.
$0.92+1.08%
BBLGBone Biologics Corporation
$1.03-4.21%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About NDRA

What is the current price of Endra Life Sciences?

Endra Life Sciences is trading at $4.73 per share.

What is the 52-week range for Endra Life Sciences?

Over the past 52 weeks, Endra Life Sciences has traded between $2.96 and $9.85.

How much debt does Endra Life Sciences have?

As of the most recent reporting period, Endra Life Sciences reported total debt of $461.21K.

How much cash does Endra Life Sciences have on hand?

Endra Life Sciences reported $356.46K in cash and cash equivalents in its most recent financial results.

What is Endra Life Sciences’s dividend yield?

Endra Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services